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Abstract
Background Chromogenic in situ hybridization (CISH) is
emerging as a practical, cost-effective, and valid alternative to
fluorescent in situ hybridization in testing for gene alteration,
especially in centers primarily working with
immunohistochemistry (IHC).
Methods We assessed Her-2/neu  alteration using CISH on
formalin-fixed paraffin-embedded primary invasive ductal
carcinoma tumors in which IHC (CB11 antibody) had previously
been performed, and we compared the results with IHC. The
160 selected cases were equally stratified randomly into the
four IHC categories (scores of 0, 1+, 2+, and 3+). We also
compared age at diagnosis and tumor histologic grade with IHC
and CISH Her-2/neu.
Results We were able to perform and evaluate CISH
successfully on all cases. The agreement between 3+ IHC and
CISH-amplified cases as well as between all IHC and CISH Her-
2/neu negative cases was 100%, and the concordance on all
positive cases was 72.50%, with an overall agreement of
86.25%. All the discordant cases had 2+ IHC scores. Although
we noted Her-2/neu positivity more in premenopausal women,
the age at diagnosis was not significantly associated with IHC
or CISH results. Similarly, although the small group of well-
differentiated tumors was apparently Her-2/neu negative in both
tests, no significant association was noted between any tumor
histologic grade and either IHC or CISH results.
Conclusions CISH is easily integrated into routine testing in our
laboratory. It is a necessary adjunct in determining the subset of
non-amplified IHC-positive invasive tumors that will not benefit
from trastuzumab therapy. Those cases with 2+ IHC results will
be triaged and subjected to CISH. Her-2/neu testing should be
done on all breast cancer cases regardless of age at
presentation and tumor histologic grade.
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Introduction
The Her-2/neu proto-oncogene, also known as c-erbB-2, is
a member of the type I growth factor receptor gene family
and is located in the long arm of chromosome 17 (17q12-
21.32) [1]. It encodes a 185 kDa cytoplasmic membrane
glycoprotein involved in tyrosine kinase signal transduction
for epithelial cell proliferation, including the breast epithe-
lium [2].
In 20–30% of breast carcinomas, Her-2/neu  status is
altered, and this is manifested either as amplification of the
gene or overexpression of the protein product [3]. Such
alteration has been associated with poor prognosis and
with resistance to conventional adjuvant chemotherapy and
tamoxifen, regardless of the nodal or hormone receptor sta-
tus [4-8]. Moreover, patients with breast carcinomas with
amplified or overexpressed Her-2/neu  can benefit from
anthracycline-based regimens as well as trastuzumab (Her-
ceptin), a recombinant humanized monoclonal antibody
against the Her-2/neu protein [9].
Tumor Her2/neu is generally assessed as protein overex-
pression by using immunohistochemistry (IHC), and
patients with tumors that either have 2+ or 3+ results with
this method become good candidates for treatment with
trastuzumab.
CISH = chromogenic in situ hybridization; FISH = fluorescence in situ hybridization; IHC = immunohistochemistry; PBS = phosphate-buffered saline; 
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However, studies indicate that Her2/neu  determined as
gene amplification provides better prognostic information
and is associated with a better response to trastuzumab
[10-12]. A subset of patients with tumors having 2+ IHC
results were found to show no response to the drug,
whereas all those having gene amplification responded
favorably. Nevertheless, a negative (0 or 1+) or a 3+ Her-
2/neu IHC correlates well with a negative or positive Her-
2/neu gene amplification, respectively.
Her-2/neu gene amplification is primarily detected by in
situ hybridization and uses fluorescence (FISH) to detect
the signals. This method is both cumbersome and expen-
sive and needs a fluorescence microscope, appropriate fil-
ters, and a sophisticated camera; it is therefore not
practical as a screening tool. Chromogenic in situ hybridi-
zation (CISH) is a recently introduced method, and
although it makes use of the in situ hybridization technology
of FISH, it also takes advantage of the chromogenic signal
detection of IHC that can be detected with the ordinary
light microscope and costs one-quarter as much as FISH.
CISH is potentially able to detect Her-2/neu gene amplifi-
cation and to minimize, if not eliminate, the false positive
fraction with the IHC procedure. Here we report an evalua-
tion of the CISH assay in St Luke's Medical Center
(SLMC), Philippines.
Methods
Inclusion criteria
This study focused on in-patient female breast cancer tis-
sue samples with final histopathologic diagnosis of invasive
ductal carcinoma of no special type, with archival paraffin
blocks, and with prior Her-2/neu alteration determined by
IHC from 1 January 2000 to 31 December 2001 in our
laboratory.
Method
IHC was previously determined with CB11 antibody
(Zymed Laboratories) on breast tumor samples fixed in
buffered formalin and embedded in paraffin. Only one
pathologist reviewed the Her-2/neu results of all IHC cases
in the period covered, reassessing them in accordance
with the US Food and Drug Administration-approved Her-
2/neu IHC scoring guidelines [10]. Immunoreactivity was
defined as negative with a score of 0 (no staining in all cells
or very weak membrane staining in less than 10% of the
tumor cells) or 1+ (weak perceptible partial membrane
staining in more than 10% of the tumor cells), and was
defined as positive with a score of 2+ (weak to moderate
complete membrane staining in more than 10% of the
tumor cells) or 3+ (strong complete membrane staining in
more than 10% of the tumor cells). Areas with intraductal
carcinoma were excluded from the evaluation.
Her-2/neu gene amplification was then analyzed with CISH
on cases selected through stratified random sampling into
the four IHC categories. Each category contained an equal
number of samples (40 samples in each IHC category), for
a total of 160 samples.
The CISH assays were run by one technologist in the His-
topathology Section of the Institute of Pathology following
the protocol of Zymed. Thereafter, CISH results were read
by the same pathologist who was blinded to the previous
IHC results. CISH was assessed on invasive ductal carci-
noma areas only; foci of intraductal carcinoma were
excluded from the analysis of results. Table 1 shows the
recommended CISH scoring by Zymed.
In addition, the patients' ages were arbitrarily grouped as
either premenopausal (less than 50 years) or postmeno-
pausal (50 years or more). The histologic grades of the
invasive tumor foci were assessed in the IHC and CISH
slides by using the modified Bloom–Richardson classifica-
tion [13].
CISH procedure for formalin-fixed paraffin-embedded 
breast cancer tissue samples
In brief, tissues 4–5 µm thick were mounted on Histogrip-
treated microscope slides, dried at 37°C, and baked for 2–
4 hours at 60°C. The slides were deparaffinized for 15 min
three times in xylene at room temperature (22–27°C) and
washed for 2 min three times in 100% ethanol at room
temperature.
The slides were microwaved in SPOT-Light Tissue Heat
Pretreatment Buffer for 10 min at 92°C and washed for 3
min twice in phosphate-buffered saline (PBS). They were
covered with 100 µl SPOT-Light Tissue Pretreatment
Enzyme for 10 min at 37°C and washed for 2 min three
times in PBS at room temperature. The slides were then
dehydrated in 70%, 85%, 95%, and 100% ethanol for 2
min each, then air-dried.
Denatured probe (15 µl) was added to the center of each
sample and covered with a 24 mm × 32 mm coverslip, the
edges of which were sealed with thin layer of rubber
cement to prevent the evaporation of probe solution during
incubation. The slides were denatured at 94°C for 3 min
and placed in a dark humidity box for 16–24 hours at 37°C.
After removal of the rubber cement and coverslip, the slides
were immersed in 0.5 × SCC buffer in a Coplin jar for 5 min
at 75°C. They were then washed for 2 min three times in
PBS-Tween 20 buffer at RT.
The slides were submerged in peroxidase quenching solu-
tion and then washed for 2 min three times with PBS, afterAvailable online http://breast-cancer-research.com/content/6/5/R593
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which endogenous biotin blocking was performed with
Reagent A (100 µl of CAS Block).
Using Zymed's SPOT-Light Detection Kit, 100 µl each of
fluorescein isothiocyanate-labelled sheep anti-digoxigenin,
horseradish peroxidase-labelled goat anti-fluorescein iso-
thiocyanate, and diaminobenzidine chromogen were
sequentially added to the slides, with three 2 min rinses
with PBS-Tween between the addition of reagents.
The slides were counterstained with 150 µl of Gill-2 hema-
toxylin and incubated for 3 min. They were then dehydrated
with a graded series of alcohol, cleared in xylene, and
mounted with a coverslip.
Statistics
All CISH data were compared with the previous IHC results
with the use of descriptive statistics and the χ2 test for
association. Similarly, age and tumor histologic grade were
correlated with the IHC and CISH Her-2/neu with the same
statistical methods. P < 0.05 was considered statistically
significant.
Results
There were a total of 681 breast cancer Her-2/neu deter-
minations in 2000–2001, 245 of which (35.98%) were in-
patient cases. Of the in-patient cases, 104 (42.45%) had
positive Her-2/neu overexpression. One hundred and sixty
in-patient cases were randomly selected for the study. The
ages ranged from 24 to 77 years, with a median of 51 and
a mean of 51.11 (standard deviation 10.86). Seventy-four
of the (46.25%) patients were less than 50 years of age.
All 160 tests were successfully performed with the Zymed
protocol for CISH. At least two detectable amplicons per
tumor nucleus were observed, and these served as the
internal control. In addition, a highly amplified positive con-
trol was run simultaneously with each test.
CISH results were evaluated with the light microscope at
low-power and high-power magnification. Diaminobenzi-
dine background staining was variably noted, but this was
not sufficient to interfere with the interpretation of the CISH
signals. Amplified cases showed at least six signals per
nucleus; distinct clustering of amplicons was also
obtained. Those cases reported as having no amplification
or low amplification were not verified further for chromo-
some 17 aneuploidy.
Table 2 shows the CISH assay outcomes of the 160 cases
in relation to the IHC category and tumor histologic grades.
Of the 160 cases, 80 were IHC positive and 80 were IHC
negative. With the CISH assay, 58 (36.25%) of the 160
cases showed Her2/neu  gene amplification. Of the 58
amplified cases, 17 (29.31%) showed low amplification
and 41 (70.69%) showed high amplification. Forty of the
58 CISH-amplified cases had 3+ IHC results, and 18 had
2+ results. Most of the tumors were of histologic grade 2
(70%), followed by grade 3 (27.5%), then grade 1 (2.5%).
Table 3 shows the correlation of CISH and IHC in 160
breast tumor samples. There was a statistically significant
difference (P = 0.000) in the percentage of those without
amplification between IHC-negative (100%) and IHC-pos-
itive (28%) cases; only positive IHC tended to have ampli-
fication. There were 22 IHC-positive cases that
subsequently showed no gene amplification with CISH, all
of which had 2+ IHC scores.
The agreement between 3+ IHC and CISH-amplified
cases was 100%. The concordance between IHC and
CISH on all negative cases was 100%, whereas the con-
cordance on all positive cases was 72.50%, with an overall
agreement of 86.25%.
Table 4 shows the association between age stratum (men-
opausal status), tumor histologic grade, IHC, and CISH.
Many more patients less than 50 years old (premenopau-
sal) seemed to be Her-2/neu  positive and amplified,
whereas more patients 50 years old and older (postmeno-
pausual) seemed to be Her-2/neu negative and non-ampli-
fied. However, these associations were not statistically
significant (P = 0.156).
Similarly, no significant association was noted between
age and histologic grade (P = 0.658).
Table 5 shows the association between results of Her2/
neu alteration with the histologic grades of the tumor. All
histologic grade 1 cases (of which there were only four) did
Table 1
Evaluation of Her-2/neu gene status using chromogenic in situ hybridization
Amplification Her-2/neu gene status
High-level >10 copies or large cluster of amplicon per nucleus in >50% of cancer cells
Low-level 6–10 copies or small cluster of amplicon per nucleus in >50% of cancer cellsa
None 1–5 copies per nucleus of cancer cellsb
aVerify gene amplification or chromosome 17 aneuploidy with SPOT-Light Chromosome 17 Centromeric Probe. bIf 3–5 copies per nucleus, verify 
chromosomal aneuploidy with SPOT-Light Chromosome 17 Centromeric Probe.Breast Cancer Research    Vol 6 No 5    Madrid and Lo 
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Table 2
Breast tumor samples and their corresponding immunohistochemistry (IHC), chromogenic in situ hybridization (CISH) results, and 
tumor histologic grade
IHC score No. of tests CISH amplification Histologic grade
Negative Low High 1 2 3
04 0 4 0 0013 3 6
1+ 40 40 0 0 3 28 9
2+ 40 22 8 10 0 24 16
3+ 40 0 9 31 0 27 13
Total 160 102 17 41 4 112 44
Table 3
Correlation of chromogenic in situ hybridization and immunohistochemistry in archival breast tumor samples
Chromogenic in situ hybridization Immunohistochemistry Total
Negative (0 and 1+) Positive (2+ and 3+)
No amplification 80 22 102
With amplification 0 58 58
Total 80 80 160
Table 4
Comparison of age strata with tumor histologic grade, immunohistochemistry and chromogenic in situ hybridization results
Parameter Age <50 Age ≥ 50 Total
Immunohistochemistry
Negative (0 and 1+) 33 (41.25%) 47 (58.75%) 80
Positive (2+ and 3+) 41 (51.25%) 39 (48.75%) 80
Total 74 86 160
Chromogenic in situ hybridization
No amplification 43 (42.16%) 59 (57.84%) 102
With amplification 31 (53.44%) 27 (46.55%) 58
Total 74 86 160
Histologic grade
1 0 (0.00%) 4 (100.00%) 4
2 53 (47.32%) 59 (52.68%) 112
3 21 (47.73%) 23 (52.23%) 44
Total 74 86 160Available online http://breast-cancer-research.com/content/6/5/R593
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not overexpress or amplify Her2/neu. No significant
association was noted between histologic grade and IHC
scores. Similarly, no association was observed between
histologic grade and CISH results.
Discussion
Her-2/neu status can be detected by analyzing the number
of gene copies by Southern blotting, PCR, or FISH, or the
amount of expressed protein can be ascertained by West-
ern blotting, enzyme-linked immunosorbent assay, or IHC.
The two most widely used methods at present are IHC and
FISH because they are able to evaluate Her-2/neu in forma-
lin-fixed paraffin-embedded archival tissues.
Most Her-2/neu  studies have been performed by IHC,
which detects overexpression of the Her-2/neu  protein
product on the cell membrane of tumor cells. This study
used the CB11 monoclonal antibody, which, like the stand-
ardized polyclonal HercepTest, is directed against the intra-
cytoplasmic domain of the Her2/neu molecule [11,14].
IHC is widely accessible and easy to perform at a reasona-
ble cost. However, this semi-quantitative procedure is
beset by technical artifacts, sensitivity differences between
different antibodies, and subjective interpretation, resulting
in interobserver variability between pathologists [15]. Stud-
ies reveal the oversensitivity of US Food and Drug Admin-
istration-approved HercepTest, with a false positive rate as
high as 50% [10,11]. Thomson and colleagues concluded
that in cases with an IHC stain intensity of 1+ or 2+, the
interobserver agreement is poor and the predictive value is
unsatisfactory for clinical use; they recommended addi-
tional testing, preferably with FISH [16].
FISH is a fairly objective and quantitative procedure in
detecting Her-2/neu gene amplification on the nuclei of
tumor cells. The drawbacks of this procedure are its steep
cost (10 times that of IHC), sophistication, the need for a
fluorescence microscope, the temporary signal (it requires
a special camera), and its inability to detect and assess
tumor histomorphology.
Her-2/neu overexpression detected by IHC is highly corre-
lated with gene amplification detected by FISH (as high as
98% concordance) [17]. However, 3–15% of breast carci-
nomas show moderate Her-2/neu membrane staining with-
out evidence of amplification. They most often represent
highly sensitive nonspecific staining (false positive) and,
rarely, either enhanced mRNA transcription in the absence
of amplification or gene amplification that is below the
detection level of in situ hybridization methods [11,18,19].
Kakar and colleagues concluded that IHC is appropriate for
the initial Her-2/neu  assessment, but patients whose
tumors scored less than 3+ (particularly those interpreted
as 2+) would benefit from FISH to assess Her-2/neu status
more accurately and to avoid inaccurate prognostication
and inappropriate treatment [20].
CISH is a recent advancement in Her-2/neu detection. It
uses a robust unique-sequence probe developed for in situ
hybridization and is a promising practical alternative to
FISH. After the first CISH study by Tanner and colleagues
[21], seven other reports favorably validated CISH results
[22-28]. The concordance between CISH and FISH
ranged from 85% [25] to as high as 100% [23,24]. All
these reports noted the advantages of CISH over FISH: it
requires an ordinary microscope; the method is less cum-
Table 5
Comparison of Her2/neu immunohistochemistry and chromogenic in situ hybridization results with tumor histologic grades
Histologic grade Immunohistochemistry Her2/neu (%)
Negative (0 and 1+) 2+ 3+
1 4 (5.00) 0 (0.00) 0 (0.00)
2 61 (76.25) 24 (60) 27 (67.50)
3 15 (18.75) 16 (40) 13 (32.50)
Histologic grade Chromogenic in situ hybridization Her2/neu (%)
No amplification With amplification
Low High
1 4 (3.92) 0 (0.00) 0 (0.00)
2 75 (73.53) 12 (70.59) 25 (60.98)
3 23 (22.55) 5 (29.41) 16 (39.02)Breast Cancer Research    Vol 6 No 5    Madrid and Lo 
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bersome and more economical; the signal intensity is
permanent; and pathologists are familiar with IHC signals
and are able to correlate findings with the underlying tumor
histomorphology. CISH allows observers to select fields of
invasive ductal carcinoma, avoiding foci of intraductal car-
cinoma for which Her-2/neu has a different clinical signifi-
cance. CISH is a specific, sensitive, and easily applicable
method for the detection of Her-2/neu gene amplification,
and it can be used together with IHC for the evaluation of
patients with breast carcinoma [22]. Ross and colleagues
recently reviewed the current status of Her-2/neu testing,
and they concluded that CISH is a more convenient gene-
based technique that is 'waiting in the wings' [29].
In this present study, the concordance between 3+ IHC
and CISH-amplified cases was 100% (40 of 40), denoting
all gene amplified cases to be overexpressing the Her-2/
neu protein. In contrast, the agreement on 2+ IHC and
CISH-amplified cases was only 45%, which is lower than
previously reported (93%) [26]. The 13.75% (22 of 160)
IHC-positive/CISH non-amplified tumors in this study, all of
which had 2+ IHC scores, is higher than the 6% false pos-
itive result by Zhao and colleagues [24], although compa-
rable to the 17% result (IHC CB11 versus FISH) obtained
by Tubbs and colleagues [11]. Apparently, we find that the
2+ IHC score is equivocal when compared with CISH. This
subset might benefit from further CISH reflex testing. All
negative IHC cases were CISH non-amplified, showing
complete agreement of all negative results. The 86.25%
overall concordance between IHC (using CB11 antibody)
and CISH in this study is lower than the previous reports
(94–96%) [24,30]. We concur with Sapino and colleagues
that gene amplification analysis can be avoided in all 0, 1+,
and 3+ IHC cases because results are predictable from
IHC and are completely concordant with CISH [30]. The
utility of CISH is therefore in further testing Her-2/neu alter-
ation on equivocal cases in IHC, which remains the primary
screening method. The combined IHC–CISH algorithm
provides an economical and comprehensive Her-2/neu
data to guide clinicians in mapping treatment options.
The low-amplified CISH category (6–10 signals) was the
most difficult to interpret, requiring an accurate enumera-
tion of gene copy. Signal clustering, more probably a result
of intrachromosomal amplification of homogeneously stain-
ing regions, was immediately apparent in highly amplified
cases and was easily evaluated [23,31].
A test for chromosome 17 aneuploidy was not performed
on non-amplified and low-amplified CISH assays, because
recent studies showed that it makes the analysis more
costly and time consuming without adding relevant data,
apart from reporting the recommended number of nuclear
amplicons and acting as another form of internal control for
the hybridization reaction [11,18,21-24]. In addition,
although the manufacturer (Zymed) suggested that chro-
m o s o m e  1 7  a n e u p l o i d y  b e  t e s t e d  o n  a l l  g e n e - a m p l i f i e d
cases, we concur with Vera-Roman and colleagues [28],
who correctly pointed out that because most polysomy
results fall within the gray area of three to five signals, set-
ting the threshold of cutoff signal points to a high of six or
more (as in this study) virtually eliminates the polysomy
variable.
This study did not observe IHC-negative CISH-amplified
tumors. This can probably be explained by the fact that this
was a single-institution study likely to have uniformly fixed
and processed tumor tissue paraffin blocks as well as a uni-
form antigen retrieval technique, both of which make high-
quality IHC easier. Zhao and colleagues reported occa-
sional IHC-negative CISH-amplified cases, and they con-
sidered that these represent a small undetermined
percentage that amplified Her-2/neu without overexpres-
sion [24]. The same study and other FISH studies also
noted rare 3+ IHC tumors that were non-amplified (false
positive) [11,24,30]. The reasons offered for the IHC–
CISH discrepancies are similar to those between IHC and
FISH, as previously stated in the present report.
The causes of testing failure and false negativity offered by
previous CISH studies were an absence of tumor on the
section, an inability to score owing to high background, a
low signal intensity despite repeated trials, an absence of
signals from the internal control, and the use of alcohol–for-
malin–acetic acid fixative [22-24,26]. It was further noted
that heat pretreatment and digestion with pepsin are the
most critical procedures for optimized CISH performance,
and that successful rates of CISH were low when 20-year-
old tissue blocks were used [24].
Sauer and colleagues [32] correlated IHC and FISH results
with clinical prognosis. They noted that IHC/FISH-positive
cases as well as FISH-positive-only cases had the same
prognosis regarding survival, whereas IHC-positive-only
cases had a prognosis similar to that of IHC/FISH-negative
tumors. In contrast, IHC-negative/FISH-positive cases had
a survival probability similar to that of IHC/FISH-positive
cases. The same authors concluded that if only IHC were
used as a primary tool, IHC-negative/FISH-positive cases
would be missed; those women would not have the benefit
of trastuzumab and their survival would be adversely
affected. In contrast, IHC-positive-only tumors seem to
belong to a better prognostic group, and failure to detect
them would probably not have a negative effect on survival
[32].
Because clinical outcome studies have yet to address the
utility of the low-amplified and high-amplified CISH results,
especially the uncertain significance of the low-amplified
group, these categories are still in flux. This limitation not-Available online http://breast-cancer-research.com/content/6/5/R593
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withstanding, there is still value in reporting such amplified
groups separately at present, pending whatever clinical
associations will be obtained in the future. Intraobserver
and interobserver variability on reporting low-amplified and
high-amplified CISH results were not included in this study,
although the pathologist who interpreted the CISH assays
consistently applied the criteria set by the manufacturers.
Breast cancer in premenopausal women has a different
biopathologic profile from that in older patients, with a pre-
dominance of unfavorable prognostic parameters, includ-
ing a higher frequency of grade 3 tumors and more frequent
Her2/neu overexpression [33]. Young age serves as a sur-
rogate measure of adverse prognostic profiles [34]. This
study failed to establish the association between menopau-
sal status, which was arbitrarily set at 50 years and above,
and Her2/neu alteration.
Her2/neu amplification was directly correlated with grade
and histologic type of breast cancer [27,30,35]. Sapino
and colleagues suggested that, on the basis of tumor grade
and histologic type, the pathologist should be able to indi-
cate to the oncologist which breast cancer requires Her2/
neu analyses [30]. However, while none of the four well-dif-
ferentiated tumors showed Her2/neu amplification or over-
expression, no significant correlation was gathered in this
study in terms of Her2/neu status and histologic grade; we
therefore still subscribe to testing Her2/neu on all newly
diagnosed breast cancers. Overall, age distribution of
breast cancer patients and tumor histologic grade did not
significantly predict IHC and CISH Her2/neu status.
Conclusion
The study has successfully evaluated Her2/neu CISH as a
molecular biology procedure that is easily integrated into
routine testing in our laboratory. CISH is a promising, prac-
tical alternative to FISH that can be used in conjunction
with IHC, which remains the first screening procedure of
choice. IHC is easy to perform, relatively inexpensive, and
able to detect a majority of breast cancer patients whose
tumors have negative (0 or 1+) or positive (3+) Her-2/neu
status, all three of which have complete concordance with
CISH.
In the SLMC laboratory setup, Her2/neu  CISH can be
done directly at the request of the physician. Because dis-
crepancies between the two Her-2/neu  tests were
observed in the 2+ IHC category, cases with 2+ IHC
results will be triaged and subjected to CISH before trastu-
zumab therapy. This IHC–CISH test stratification not only
identifies the IHC false-positive subset that will not benefit
from trastuzumab but also keeps testing costs for Her-2/
neu status at a reasonable minimum.
Her2/neu testing has achieved a standard-of-practice sta-
tus in the USA [28], and it should be performed on all
breast cancer cases regardless of age at presentation and
tumor histologic grade.
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